As obe­si­ty mar­ket heats up, Am­gen leaves clues on Mar­i­Tide’s path for­ward

Am­gen of­fered a glance at plans for its obe­si­ty drug can­di­date Mar­i­Tide dur­ing its fourth-quar­ter earn­ings call, in­clud­ing the ex­ten­sion of an on­go­ing Phase II …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER